FASLG and glioblastoma: Previous research in patients with recurrent glioblastoma indicated that low methylation at the CpG2 site within the CD95L promotor was associated with a greater response to asunercept and radiotherapy versus high methylation (hazard ratio 0.19; 95% CI, 0.06–0.58)9.